Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis

Table 1 Population, Intervention, Comparison, Outcome, and Study design

Query	Search term
#1	P (Neoplasm, Stomach[Title/Abstract] OR Stomach oplasm[Title/Abstract] OR Neoplasms, Stomach[Title/Abstract] OR Gastric Neoplasms[Title/Abstract] OR Gastric Neoplasm[Title/Abstract] OR Neoplasm, Gastric[Title/Abstract] OR Cancer of Stomach[Title/Abstract] OR Stomach Cancers[Title/Abstract] OR Gastric Cancer[Title/Abstract] OR Cancer, Gastric[Title/Abstract] OR gastroesophageal junction cancer[Title/Abstract] OR gastroesophageal junction adenocarcinoma[Title/Abstract] OR adenocarcinoma gastroesophageal junction[Title/Abstract])
#2	I (Checkpoint Inhibitors, Immune[Title/Abstract] OR Immune Checkpoint Inhibitor[Title/Abstract] OR PD-L1 Inhibitors[Title/Abstract] OR PD L1 Inhibitors[Title/Abstract] OR PD-L1 Inhibitor[Title/Abstract] OR PD L1 Inhibitor[Title/Abstract] OR CTLA-4 Inhibitors[Title/Abstract] OR CTLA 4 Inhibitors[Title/Abstract] OR ipilimumab[Title/Abstract] OR ticilimumab[Title/Abstract] OR nivolumab[Title/Abstract] OR pembrolizumab[Title/Abstract] OR pidilizumab[Title/Abstract] OR atezolizumab[Title/Abstract] OR durvalumab[Title/Abstract] OR avelumab[Title/Abstract])
#3	O (immune-related adverse events[Title/Abstract] OR immune related adverse events checkpoint inhibitors[Title/Abstract] OR immune related adverse events checkpoint blockade[Title/Abstract] OR management of immune related adverse events[Title/Abstract] OR immune related adverse events in patients[Title/Abstract] OR immune related adverse events systemic immunosuppression[Title/Abstract])
#4	S ("randomized controlled trial"[pt] OR "controlled clinical trial"[pt] OR randomized[tiab] OR placebo[tiab] OR "drug therapy"[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab] OR "randomized controlled trial"[pt] OR "controlled clinical trial"[pt] OR "clinical trials as topic"[mesh] OR "random allocation"[mesh] OR "double-blind method"[mesh] OR "single-blind method"[mesh])
#5	#1 AND #2 AND #3 AND #4

PD-1: Programmed cell death receptor-1; PD-L1: Programmed death receptor-ligand 1; CTLA-4: Cytotoxic T lymphocyte-associated antigen-4.